GLYC News and Press, GlycoMimetics Inc. From 04/26/23

GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2023 financial results on Wednesday, May 3, 2023, at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with dia...

2023-04-04 08:35:08 ET Summary Its lead drug candidate is in Phase 3 development for multiple leukemia indications. Mechanism has utility in other cancer and non-cancer diseases. Perceived trial delays punished the stock. Delays actually raise the odds of greater survival ...

2023-03-29 11:09:04 ET GlycoMimetics, Inc. (GLYC) Q4 2022 Results Conference Call March 29, 2023 08:30 AM ET Company Participants Christian Dinneen-Long - General Counsel and Company Secretary Harout Semerjian - Chief Executive Officer Brian Hahn - Chief Financia...

2023-03-29 07:04:13 ET GlycoMimetics press release ( NASDAQ: GLYC ): Q4 GAAP EPS of -$0.19 misses by $0.02 . Cash and cash equivalents as of December 31, 2022 were $47.9 million. Cash and cash equivalents expected to fund current operations to year end 2024 ...

Significant progress in strengthening leadership, raising capital, and preparing for final results of the uproleselan Phase 3 study in relapsed/refractory (R/R) acute myeloid leukemia (AML) Interim utility analysis used high statistical threshold and resulted in independent Data Monitoring Co...

GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2022 full year financial results on Wednesday, March 29, 2023, at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be...

2023-03-13 04:02:42 ET In wake of the bank's collapse with turmoil surrounding Silicon Valley Bank, several smaller pharma, biotech companies and health care equipment have come out and said they have exposure to FDIC-shuttered Silicon Valley Bank ( SIVB ). Among the biotec...

2023-03-08 23:20:14 ET Summary Independent Data Monitoring Committee interim analysis concludes that the phase 3 study, using uproleselan in combination with chemotherapy for the treatment of relapsed/refractory AML patients should continue as planned. Last event to trigger final ...

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in the Leukemia Panel at the Cowen 43 rd Annual Health Care Conference in Boston, MA on Wednesday, March 8, 2023 at 12:50 p.m. ET. A live webcast of the panel presentation w...

Shares of clinical-stage biotech GlycoMimetics ( NASDAQ: GLYC ) lost ~6% pre-market Wednesday after the company announced the resignation of its co-founder and Chief Scientific Officer, Dr. John Magnani, effective Mar. 31. The departure follows an agreement between GlycoMimetics (...